为时未晚:近距离放疗在局部晚期宫颈癌治疗中比时机更重要
基于美国国家癌症数据库2004至2015年诊断的II-IVA期宫颈癌患者,评估近距离放疗使用和治疗时长对总生存的影响。接受标准治疗(同步放化疗加近距离放疗且8周内完成)者总生存显著改善,中位OS 131.0个月 vs 95.5个月、78.1个月、49.2个月(P<0.0001);治疗超过8周者中,近距离放疗仍与生存改善相关(中位OS 95.5 vs 49.2个月,P<0.0001)。
要点
- 仅29.3%的局部晚期宫颈癌患者接受了8周内完成的标准治疗。
- 接受标准治疗者中位OS 131.0个月,未接受标准治疗者为95.5、78.1、49.2个月(P<0.0001)。
- 治疗超过8周者中,近距离放疗仍与生存改善相关(中位OS 95.5 vs 49.2个月,P<0.0001)。
核心结论
- 在推荐的8周内完成同步放化疗和近距离放疗的标准治疗与更优的总生存相关。
- 无论治疗时长如何,接受近距离放疗加量的患者生存优于单纯体外放疗的患者。
- 弱势人群中的治疗差异凸显了宫颈癌患者治疗协调的挑战和重要性。
研究设计与样本
- 查询美国国家癌症数据库(NCDB),识别2004至2015年在美国诊断、接受根治性放化疗的II-IVA期宫颈癌患者。
- 标准治疗定义为接受体外放疗(EBRT)和同步化疗、近距离放疗(BT),并在8周内完成治疗;将标准治疗与非标准治疗进行比较。
- 主要结局为总生存(OS);同时评估社会人口学和临床变量对接受标准治疗的影响。
主要发现
- 共识别10172例以化疗和同步EBRT为主要治疗的局部晚期宫颈癌女性,其中6047例(59.4%)接受了近距离放疗,仅2978例(29.3%)在8周内完成治疗(标准治疗)。
- 接受标准治疗与总生存显著改善相关(中位OS 131.0个月 vs 95.5个月、78.1个月、49.2个月;P<0.0001)。
- 在治疗超过8周的患者中,近距离放疗仍与生存改善相关(中位OS 95.5 vs 49.2个月,P<0.0001)。
- 更晚期分期、非西班牙裔黑人种族、较低收入、无保险或政府保险、较低教育程度和农村居住与接受标准治疗的可能性降低相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the utilization of brachytherapy and duration of treatment on overall survival for locally advanced cervical cancer. METHODS: The National Cancer Database (NCDB) was queried to identify stage II-IVA cervical cancer patients diagnosed in the United States between 2004 and 2015 who were treated with definitive chemoradiation therapy. We defined standard of care (SOC) treatment as receiving external beam radiation therapy (EBRT) and concurrent chemotherapy, brachytherapy (BT), and completing treatment within 8 weeks, and compared SOC treatment to non-SOC. The primary outcome was overall survival (OS). We also evaluated the effect of sociodemographic and clinical variables on receiving SOC. RESULTS: We identified 10,172 women with locally advanced cervical cancer primarily treated with chemotherapy and concurrent EBRT of which 6047 (59.4%) patients received brachytherapy, and only 2978 (29.3%) completed treatment within 8 weeks (SOC). Receipt of SOC was associated with significantly improved overall survival (median OS 131.0 mos vs 95.5 mos, 78.1 mos, 49.2 mos; p < 0.0001). Furthemore, in patients whose treatment extended beyond 8 weeks, brachytherapy was still associated with an improved survival (median OS 95.5 vs 49.2 mos, p < 0.0001). More advanced stage, Non-Hispanic Black race, lower income, lack of insurance or government insurance, less education, and rural residence were associated with decreased likelihood of receiving SOC. CONCLUSIONS: Completing standard of care concurrent chemoradiation therapy and brachytherapy in the recommended 8 weeks was associated with a superior overall survival. Patients who received brachytherapy boost show superior survival to patients receiving EBRT alone, regardless of treatment duration. Disparities in care for vulnerable populations highlight the challenges and importance of care coordination for patients with cervical cancer.
引用
- Korenaga TK, Yoshida EJ, Pierson W, et al. Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Gynecol Oncol. 2021. PMID: 34865860. doi:10.1016/j.ygyno.2021.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。